About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 113 blog entries.

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By | 2018-06-29T07:28:14+00:00 June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By | 2018-06-08T16:28:40+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By | 2018-06-08T08:10:58+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

Esketamine nasal spray prevails in phase 3 trials

By | 2018-06-06T07:29:40+00:00 June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

MDMA-Assisted Psychotherapy Improves PTSD

By | 2018-06-05T15:12:24+00:00 June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

Letter to the Editor: The Utilization of Atypical Antipsychotics in the Pain Medicine Physician’s Armamentarium

By | 2018-06-08T16:47:30+00:00 June 5th, 2018|Uncategorized|

By Omar Viswanath MD Dear Editor, I read with great interest the recent article by Jimenez et al, A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. The article states “many psychopharmacologic agents are used as primary or adjuncts in pain [...]

An Alzheimer’s Antibiotic Receives Initial Funding

By | 2018-06-01T09:11:54+00:00 June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By | 2018-06-08T16:47:33+00:00 May 24th, 2018|Uncategorized|

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature

By | 2018-06-08T16:48:07+00:00 May 24th, 2018|Uncategorized|

By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported the interesting case of a 19-year-old woman who presented with cyclical changes in mood and behavior, alternating between depression and [...]

A Review of Clinical Literature: Stimulants, Insomnia and Psychiatric Comorbidity in Veterans

By | 2018-05-11T16:26:32+00:00 May 11th, 2018|We Know Psychiatry|

Prescription Stimulant Use, Misuse, and Motivations Approximately 16 million US adults used prescription stimulants in the preceding year (annual average), 5 million misused prescription stimulants without use disorders, and 0.4 million had use disorders, according to a recent study. Researchers conducted a nationally representative household population study of adults aged [...]